TScan Therapeutics, Inc.
NASDAQ:TCRX
Overview | Financials
Company Name | TScan Therapeutics, Inc. |
Symbol | TCRX |
Currency | USD |
Price | 2.63 |
Market Cap | 140,364,670 |
Dividend Yield | 0% |
52-week-range | 2.6 - 9.69 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Gavin MacBeath Ph.D. |
Website | https://www.tscan.com |
An error occurred while fetching data.
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD